Dendreon's $93,000 Cancer Drug Price Must Be Paid by U.S.,
Doctors Say
2 August 2010
By Tom Randall, Bloomberg.com
Dendreon Inc.'s $93,000 price tag for its Provenge prostate
cancer treatment must be covered under the rules of the U.S.
Medicare health plan, according to a letter submitted by the
American Society of Clinical Oncology.
Full article
DISCLAIMER
The links and content above are provided for your convenience to provide further information and do not constitute an endorsement by Bavarian Nordic. We have no control over the nature, content and availability of the sites that are being linked to and thus we assume no responsibility for the privacy practices on such websites.
